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Abstract. Background: Hepatocellular carcinoma (HCC)
represents the fifth most common malignancy and the third
cancer-related cause of death worldwide. The aim of this
review was to clarify the role of local treatments for HCC,
analyzing the indications and defining future perspectives.
Materials and Methods: A systematic literature search was
performed independently by two of the authors according to
the PRISMA statement guidelines. The search was limited to
studies reported in English between January 2005 and June
2016. Results: The literature search yielded 238 articles;
after duplicates were removed, 179 titles and abstracts were
reviewed. Most relevant data and articles about
radiofrequency ablation, transarterial chemoembolization,
percutaneous ethanol injection, microwave ablation and
radioembolization are reported and discussed. Conclusion:
Data in the literature are confusing and difficult to compare
due to the lack of prospective studies. Multidisciplinary and
tailored approaches for each patient are key features,
considering both guideline indications and patient-specific
characteristics, and enhance hospital-specific best practice.
Despite the advances in oncological and surgical treatments,
hepatocellular carcinoma (HCC) is still a global burden,
representing the fifth most common malignancy and the third
cancer-related cause of death worldwide (1). In the US, the
incidence of HCC has almost tripled in the last 30 years, and
it is the fastest rising cause of cancer-related deaths (2). HCC
prevalence varies worldwide: the highest incidence is
registered in Asia (>20 cases/100,000) than in North America
and Europe (<5 cases/100,000) (1). Interestingly, the analysis
of the Italian Liver Cancer database by Santi et al. published
in 2012 showed significantly better survival for patients with
HCC and cirrhosis recruited more recently compared to their
counterparts recruited 20 years earlier. However, this trend
was no longer confirmed over the subsequent 10 years (3).
HCC outcomes have improved over time in Italy, mainly due
to wider application of surveillance and increased propensity
to treat patients (4). Therefore, early diagnosis represents a
crucial step in the global approach to HCC.
For a better understanding of the screening and surveillance
protocols, we first need to reiterate the risk factors and causes
of HCC. In 70-90% of cases, HCC develops in patients with
chronic liver disease, and risk factors depend on the region
where the studies are conducted. For example, while hepatitis
C virus (HCV) infection is a major factor in Europe, Japan
and North America accounting for 50% to 70% of cases, HBV
is responsible for 10-15%, alcohol for 20% and other causes
for 10%. Conversely, in Asia and Africa, HBV is associated
with 70% of cases and HCV with 20%. Depending on the
study, the relative risk of developing a tumor is close to 100-
fold in HBV carriers versus non-carriers, while the incidence
of HCC in individuals with cirrhosis due to HCV is 3-5% per
year (1). The comorbidities of each patient can modify the risk
of developing an HCC in the presence of cirrhotic
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degeneration of the liver. The highest 5-year cumulative risks
are seen in those with HCV-associated cirrhosis (17% in the
West and 30% in Japan), hemochromatosis (21%), HBV-
associated cirrhosis (10% in the West and 15% in Asia),
alcoholic cirrhosis (8-12%), and biliary cirrhosis (4%) (2).
Alcohol abuse is a well-known cause of chronic liver disease
and cirrhosis. Heavy alcohol intake is defined as the ingestion
of more than 50-70 g per day for prolonged periods (2). In
addition, the association between the increased risk of HCC
in heavy alcohol drinkers and genetic polymorphisms of the
enzymes participating in the metabolic pathway of ethanol,
and in particular the frequency of aldehyde dehydrogenase 2
(ALDH2) genotype polymorphism, has been proposed as a
mechanism by which HCC develops (5). Among non-viral-
related HCC cases, hereditary hemochromatosis confers an
elevated risk. As shown in literature, patients diagnosed with
hereditary hemochromatosis who died were 23-fold more
likely to have liver cancer compared to those without a
diagnosis of hemochromatosis (5). Metabolic syndrome also
plays a pivotal role: non-alcoholic fatty liver disease
(NAFLD), the liver manifestation of metabolic syndrome, has
become the most common liver disease in the Western world
and its progression results in cirrhosis (6, 7). In fact, NAFLD
confers both additive and independent risk to the development
of HCC: 65% of HCCs developing in patients with metabolic
syndrome occurred in livers with mild fibrosis, compared to
20% in those with other causes of HCC. However, once
cirrhosis is established in NAFLD, the risk of HCC may be
similar to that seen in cirrhosis due to HCV (6). Although the
association between increasing body mass index (BMI) and
HCC is much stronger in individuals with concomitant HCV
infection than in persons with HBV infection (2), recent
studies demonstrated a significantly increased risk of HCC
among obese [odd ratio (OR)=3.5, 95% confidence Interval
(CI)=1.3-9.2] or diabetic (OR=3.5, 95% CI=1.6-7.7) patients
without viral hepatitis, and a high prevalence in cryptogenic
cirrhotic patients (5). As a matter of fact, the association
between BMI and liver cancer is independent of geographic
location, alcohol consumption, and history of diabetes (2).
Lastly, aflatoxin B1 exposure, tobacco use, coffee
consumption, use of oral contraceptives and betel quid are
other proven risk factors of HCC (2, 5). Of note, HIV-positive
patients with HCC had a significantly shorter survival time
than HIV-negative counterparts (8). 
The comprehension of HCC development is made even
harder when considering how many molecular pathways and
genetic alterations are involved. p53/RB, WNT/β-catenin,
PI3K/PTEN/AKT/mTOR and Hedgehog are the pathways
most well-known to play an important role in the
development and progression of HCC (9). Moreover, it was
demonstrated that HBx, a multifunctional protein encoded by
the HBV genome, plays a pro-carcinogenic role, since it has
the ability for the transcriptional transactivation and can
activate the JAK/STAT signaling pathway but impair the p53
function (9). It has been demonstrated that 90% of human
HCCs have increased telomerase expression. The
mechanisms of telomerase reactivation are mutually
exclusive and include telomerase reverse transcriptase
(TERT) promoter mutations (54-60%), TERT amplification
(5-6%), and HBV insertion into the TERT promoter (10-
15%) (10). Tumor–stromal communication and epithelial to
mesenchyme transition are also important factors
participating in tumor progression (11-13). Interestingly, long
non-coding RNAs also seem to be strongly associated with
liver cancer, with a potential role as biomarkers for disease
diagnosis, prognosis, or therapeutic response, as well as
being direct targets for therapeutic intervention (14).
Both Western (American Association for the Study of Liver
Diseases and European Association for the Study of the Liver)
and Eastern (Asian Pacific Association for the Study of the
Liver and Japan Society of Hepatology) guidelines are
available for HCC surveillance and screening. Screening is
recommended in patients with: (i) cirrhosis of any etiology,
with conserved liver function [Child–Turcotte–Pugh (CTP)
class A and B], lacking severe comorbidities; (ii)
decompensated cirrhosis (CTP C) on a transplant waiting list;
(iii) non-cirrhotic chronic HBV infection with active hepatitis
or a family history of HCC; and iv) non-cirrhotic HCV
infection and advanced liver fibrosis (F3) (1). Recently,
surveillance ultrasound imaging of the liver every 6 months has
increased reliability versus the use of serum levels of alpha
fetoprotein (AFP), the classical HCC marker, due to poor
sensitivity of AFP (6, 15). Other markers such as glypican-3,
heat-shock protein 70 and SAL-like protein 4 are promising
but currently not validated (9, 11). Computed tomography (CT)
can be proposed for screening in obese patients due to technical
issues on ultrasound performance (6). However, CT is always
indicated when a lesion is suspected on ultrasound: intense
arterial uptake, followed by washout of contrast in the venous
phase, is the hallmark radiological sign of HCC (15).
According to the most recent trends, nodules <1 cm do not
correspond to an HCC in most cases, and even when they do,
confident diagnosis is currently almost impossible to be
achieved. Follow-up with ultrasound scan of those small
nodules should be performed over time until they grow beyond
1 cm or vanish (16). This is because biopsy of such small
lesions in patients with cirrhosis is not completely reliable:
sampling errors and difficulty in distinguish well-differentiated
HCC from dysplastic nodules must always be considered,
making it impossible to rule out malignancy on the basis of a
negative biopsy (16). While Eastern societies always include
contrast enhanced ultrasound (CEUS) in the diagnostic
pathway, Western societies do not consider CEUS an
appropriate study in the diagnostic approach to HCC, due to
the theoretical difficulty in differentiating HCC from
cholangiocarcinoma (1). 
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Several classification and staging systems have been
proposed for the management of HCC. As a matter of fact,
such a variety hides the latent difficulty in adopting a
really functional algorithm. CTP (17), Model for End-
stage Liver Disease (MELD) (18), TNM classification
(19), tumor volume estimation (20), and evaluation of the
patient’s Eastern Cooperative Cancer Group (ECOG)
performance status (21), are well-known systems but the
most used is the Barcelona Clinic Liver Cancer staging
system (BCLC) (22). BCLC is a multidimensional
platform based on patient’s performance status, liver
function (calculated using the CTP score) and tumor
dimensions that stratifies HCC severity and consequent
therapeutic approaches into five categories. According to
that system, very early (BCLC 0) and early stages (BCLC
A) are amenable to curative treatments, such as tumor
resection, liver transplantation and tumor ablation. In the
first category, radical treatments can completely eradicate
the tumor, while in the second, the survival does not
exceed 3 years if HCC is not treated. On the other hand,
intermediate-stage (BCLC B) HCC can benefit from
transarterial chemoembolization (TACE), improving
median survival to more than 24 months compared to 16
months without treatment. Advanced-stage (BCLC C)
HCC can be treated with Sorafenib: it was the only
therapy that demonstrated some survival benefit,
compared to the average survival of 8 months for patients
at this stage without any treatment. Lastly, terminal stage
(BCLC D) HCC requires only supportive care (1).
However, given its heterogeneity and the intricate
background of HCC development, the therapeutic
approach should always be multidisciplinary and patient-
tailored in order to offer the best treatment possible (23,
24). Notably, the BCLC system is not rigid and should be
used with the consideration that a patient being evaluated
for therapy may move from the indication corresponding
to an early stage to that of intermediate or advanced stage
because of a specific patient profile that may
contraindicate the initially optimal approach, reflecting
the ‘treatment stage migration’ concept (16). This
demonstrates the importance of developing optimal down-
staging strategies to make patients move backwards to
‘earlier’ stages that can benefit from therapeutic
approaches. In fact, although there are no randomized
trials assessing the benefit of treatment of patients on the
transplant waiting list, it seems reasonable and is a
common practice to treat patients either with percutaneous
ablation or TACE to prevent progression and bridge
patients to liver transplantation when the waiting time is
longer than 6 months (16). 
The aim of this review was to clarify the role of local
treatments for HCC, analyzing the current indications and
defining future perspectives.
Materials and Methods
Literature search. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement guidelines for
conducting and reporting systematic reviews were followed (25). 
A systematic literature search was performed independently by
two of the Authors (PM and GT) using PubMed, EMBASE, Scopus
and the Cochrane Library Central. The search was limited to studies
in humans and to those reported in the English language between
January 2005 and June 2016. No restrictions were set for the type
of publication. Participants of any age and sex who underwent local
treatment for HCC were included in this study. 
The following MeSH search headings were used: “hepatocellular
carcinoma” OR “HCC” OR “hepatoma” AND “TACE” OR
“radiofrequency ablation” OR “PEI” OR “microwave” OR
“radioembolization” OR “local treatment”. Extensive crosschecking
of the reference lists of all retrieved articles that fulfilled the
inclusion criteria further broadened the search. For all of the
databases, the last search was run on June 1st, 2016.
Study selection. The same two Authors screened the titles and
abstracts of the primary studies that were identified in the electronic
search. The following criteria were adopted for inclusion in this
review: (i) Studies comparing the outcomes of different local
treatments; (ii) studies reporting at least one perioperative outcome;
and (iii) if more than one study was reported by the same institute,
only the most recent or the highest quality study was included.
The following exclusion criteria were set: (i) Original studies
assessing the outcome of surgical approach alone; (ii) review
articles, letters, comments and case reports; and (iii) studies in
which it was impossible to retrieve or calculate data of interest. 
The literature search yielded 238 articles; after duplicates were
removed, 179 titles and abstracts were reviewed. The most relevant
data and articles are reported in the results section and later discussed.
Data extraction. The main data were extracted as follows: (i) First
author, year of publication and study type; (ii) number and
characteristics of patients and (iii) treatment outcomes including
hospital stay, mortality rate, recurrence rate, 5-year overall survival
and 5-year disease-free survival. All relevant texts, tables and
figures were reviewed for data extraction and whenever further
information was required, the corresponding authors of the papers
were contacted by e-mail. 
Discrepancies between the two reviewers were resolved by
consensus discussion or with the opinion of the senior author
(FDB). Results are summarized in Tables I-III.
Results
Ablative therapies: Radiofrequency ablation (RFA) –
percutaneous ethanol injection (PEI) – microwave. HCC can
be treated with RFA in several conditions. In 2015, Kim and
colleagues reported their experience in a retrospective study
of 604 consecutive patients affected by small HCCs (<3 cm)
and treated between 2000 and 2009 with either surgery (273
patients) or RFA (331 patients) (26). Inclusion criteria were:
(i) well preserved liver function of CTP class A; (ii) normal
serum bilirubin level (less than 1.5 mg/dl); and (iii) no
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definite evidence of portal hypertension, as assessed
clinically. They reported that 5- and 10-year HCC-specific
survival rates were 87.6% and 59.0% respectively for the
resection group with a median survival of 61 months, and
82.1% and 61.2%t respectively for the RFA group with a
median survival of 66 months (p=0.214). The recurrence rate
was higher in the group treated by RFA (59.8%, 198 patients)
than in the group treated by surgical resection (42.1%, 115
patients) (p<0.001), and the median overall recurrence-free
survival was shorter in the RFA group (36 months; 39.4% at
5 years and 25.1% at 10 years) than in the resection group
(44 months; 60.6% and 37.5%, respectively) (p<0.001).
The approach to recurrent HCC after RFA was discussed
by Xie et al. (27). Among 50 patients that were initially
treated by RFA, 27 underwent repeated RFA for local
recurrence, 20 underwent salvage surgery, and three
underwent TACE. The overall survival rates for patients after
RFA were 85.2% and 52.6% at 1 and 3 years, respectively,
and 91.7 and 78.6%, respectively, for patients after salvage
surgery (p=0.374). Data of patients that underwent TACE
were unfortunately unavailable. At multivariate analysis, low
serum albumin [hazard ratio (HR)=1.320; 95% confidence
interval (CI)=1.029-1.693; p=0.029), increased number of
tumors (HR=1.312; 95% CI=1.044-1.649; p=0.020),
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Table I. Outcomes of the most relevant articles on tumor ablation.
Author (Ref)                    Year    No. of patients   Type of study   Study interval                 Study design                                 Major outcomes
Signoriello et al. (29)     2012             425                    R/M             1998-2002         Patients treated with local             No statistically significant 
                                                                                                                                       approach were compared             difference comparing RFA 
                                                                                                                                            to evaluate overall                   versus PEI, surgery versus
                                                                                                                                        survival with a median               TACE/TAE, and RFA/PEI 
                                                                                                                                        follow-up of 7.7. years                       versus TACE/TAE
Chang et al. (28)            2012              39                     R/S              2002-2007        Patients with incompletely             Local recurrence-free and 
                                                                                                                                           treated single HCC                survival rates are comparable 
                                                                                                                                           (≤5 cm) after TACE                as demonstrated in previous 
                                                                                                                                         were treated with RFA               studies of RF ablation alone
Lin et al. (31)                 2013            1036                   R/M             2004-2006          Patients receiving PEI or                RFA is related to better 
                                                                                                                                  RFA as first-line treatment for              OS compared to PEI 
                                                                                                                                     newly-diagnosed stage I-II              regardless of tumor size
                                                                                                                                           HCC were enrolled                                         
Zhang et al. (32)             2013             155                    R/S                   2006              Patients receiving PEI or           RF ablation and MW ablation 
                                                                                                                                  RFA as first-line treatment for         are both effective methods 
                                                                                                                                     newly-diagnosed stage I-II             in treating hepatocellular 
                                                                                                                                           HCC were enrolled               carcinomas, with no significant 
                                                                                                                                                                                      differences in CA, LTP, DR, and OS
Hasegawa et al. (30)      2013           12968                  R/M             2000-2005          Evaluate the outcomes in             OS and time to recurrence 
                                                                                                                                  patients treated by SR, PEI, or       rates were both significantly 
                                                                                                                                       RFA, with no more than             better in the SR group than 
                                                                                                                                            3 tumors and liver                         in the RFA and PEI 
                                                                                                                                        damage of class A or B                                     
Kim et al. (26)                2016             604                    R/S              2000-2009             Patients with a single          RFA treatment was independently 
                                                                                                                                  asymptomatic HCC <3 cm and   associated with poorer outcomes 
                                                                                                                                       good health performance              in terms of treatment-site 
                                                                                                                                         status, who underwent                  recurrence-free survival
                                                                                                                                         liver resection or RFA
Xie et al. (27)                 2015              70                     R/S              2008-2013         Evaluate the outcomes of               Survival outcomes after 
                                                                                                                                   salvage treatments (SS, RFA,       repeated RFA were similar to 
                                                                                                                                        TACE) for RFA-related                   those achieved by SS
                                                                                                                                       local recurrence of HCC                                    
Ginsburg et al. (33)        2015              89                     R/S              2003-2011        Compare the outcomes and            No statistically significant 
                                                                                                                                    complications of TACE with            difference between those 
                                                                                                                                    drug-eluting embolic agents          two approaches in terms of 
                                                                                                                                    combined with RFA or MW             overall progression-free 
                                                                                                                                   ablation in treatment of HCC                   survival and OS
CA: Complete ablation; DR: distant recurrence; HCC: hepatocellular carcinoma; LTP: local tumour progression; M: multicentric; MW: micro wave;
OS: overall survival; P: prospective; PEI: percutaneous ethanol injection; R: retrospective; RFA: radiofrequency ablation; RT: randomized trial; S:
single center; SR: surgical resection; SS: salvage surgery; TACE: trans-arterial chemo-embolization. 
increased maximum tumor size (HR=1.449; 95% CI=1.125-
1.866; p=0.004), and increased serum AFP level (HR=1.336;
95% CI=1.223-1.527; p<0.004) were significant prognostic
factors for recurrence after initial RFA, while increased
number of tumors (HR=2.934; 95% CI=1.012-8.521;
p=0.048) was the only significant prognostic factor for
recurrence after repeat RFA.
In their work published in 2012, Chang and colleagues
discussed the role of RFA after incomplete TACE in a
retrospective single-center study of 39 patients (28). The
inclusion criteria for the study were: a single HCC smaller
than or equal to 5 cm in diameter; lesions visible on
ultrasonography (US), with an acceptable and safe path
between the lesion and the skin as observed on the US scan;
no extrahepatic metastases present; no imaging evidence of
tumor invasion into the major portal or hepatic vein
branches; liver cirrhosis classified as CTP class A or B; no
history of encephalopathy, ascites refractory to diuretics, or
variceal bleeding; and no previous treatment for HCC except
TACE. Complete tumor ablation depicted on dynamic CT
performed 1 month after treatment was achieved in 36
(92.3%) out of 39 patients, with no procedural deaths and a
complication rate of 5.1% (two patients). The overall
survival rates at 1, 2, 3, and 5 years, were 96.9%, 82.9%,
67.8%, and 48.4%, respectively. While increasing tumor
diameter was found to be a significant prognostic factor
affecting local recurrence (p=0.047), no significant
prognostic factors affecting overall survival rate were found. 
In 2012, Signoriello et al. reported a multicentric Italian
experience comparing the outcomes of patients affected by
HCC and treated with local approaches (29). A total of 425
patients were included, with a median follow-up of 7.7 years.
PEI was the most common treatment (60%) followed by
either TACE or transarterial embolization TAE) (19%), while
RFA was performed in fewer cases. The authors did not find
any statistically significant differences in terms of overall
survival between the three comparisons they made, namely
RFA versus PEI, surgery versus TACE/TAE, and RFA/PEI
versus TACE/TAE. 
In 2013, Hasegawa and colleagues reported their
outcomes from a large cohort of patients who underwent
surgical resection, PEI, or RFA, with no more than three
tumors and liver damage of class A or B (30). They reported
that overall survival rates at 3 and 5 years were 85.3 and
71.1% in the surgically-resected group, 81.0 and 61.1% in
the RFA group, and 78.9 and 56.3% in the PEI group; the
median survival times were 8.4, 5.9, and 5.6 years in the
three groups, respectively. The recurrence rates at 3 and 
5- years in the three groups were 43.3 and 63.8%, 57.2 and
71.7%, and 64.3 and 76.9%, respectively. These results
indicate that the overall survival and recurrence rates were
both significantly better in the surgically resected group than
in the RFA and PEI groups (p=0.006 and p=0.0001,
p=0.0001 and p=0.0001, respectively). 
Lin and colleagues compared the efficacy of RFA to that
of PEI in early-stage HCC in their article published in 2013
(31), in which 1,036 patients from the Taiwan Cancer
Registry were included according to the following criteria:
HCC as the primary tumor; stage I or II tumor according to
the American Joint Cancer Committee on Cancer (AJCC)
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Table II. Outcomes of the most relevant studies on Trans-Arterial Chemo-Embolization (TACE).
Author (Ref)                    Year    No. of patients   Type of study   Study interval                 Study design                                 Major outcomes
Kirikoshi et al. (34)        2009             253                    R/S              1995-2007      Evaluate the effects of TACE          TACE alone yielded better 
                                                                                                                                  and of the combined therapies           outcomes than palliative 
                                                                                                                                 (TACE + PEI or TACE + RFA)      treatment, combined TACE + 
                                                                                                                                  on the long-term survival rates         PEI/RFA therapy was more 
                                                                                                                                                                                             useful than TACE alone for 
                                                                                                                                                                                             patients with a single tumor
Jin et al. (35)                  2014              68                     R/S              1998-2012           Compare the treatment             TACE provides significantly 
                                                                                                                                   outcomes of surgery/RFA and              better OS rate among 
                                                                                                                                     TACE in recurrent HCC of       recurrent MVI-positive patients 
                                                                                                                                           BCLC stage 0 or A                      than surgery/RFA after 
                                                                                                                                                                                              curative resection for HCC
Wang et al. (36)              2015             629                     P/S              2004-2010      Patients with HCC recurrence         Re-hepatectomy group had
                                                                                                                                    after curative resection were          significantly better OS than 
                                                                                                                                   grouped into re-hepatectomy,      the RFA group, and that of the 
                                                                                                                                               RFA, or TACE                     RFA group was significantly 
                                                                                                                                                                                             better than the TACE group 
HCC: Hepatocellular carcinoma; M: multicentric; MVI: microvascular invasion; OS: overall survival; P: prospective; PEI: percutaneous ethanol
injection; R: retrospective; RFA: radiofrequency ablation; RT: randomized trial; S: single center; TACE: trans-arterial chemo-embolization. 
system, 6th edition; PEI or RFA as the first course of
treatment within one year of diagnosis; age >18 years. The
exclusion criteria were as follow: reported prior cancer;
multiple primary cancers; histological type with lymphoma
(M-code: 9590-9989), or Kaposi’s sarcoma (M-code: 9140).
RFA led to a significantly better overall survival than PEI,
83% and 71%, respectively, at 2 years post-diagnosis and
55% and 42% at 5 years (p<0.001).
Zhang and colleagues reported the outcomes of 155
patients who underwent either RFA (78 patients) or
microwave ablation (77 patients) in a retrospective study (32).
Inclusion criteria were a solitary HCC lesion of 5 cm in
greatest diameter or smaller; three or fewer multiple HCC
lesions with a greatest diameter of 3 cm or less; no
radiological evidence of vascular invasion and extrahepatic
metastases; index tumors with no prior treatment; liver
function classed as CTP class A; prothrombin time of less
than 22 s and platelet count higher than 45 cells6109/l; no
history of ascites refractory to diuretics, variceal bleeding, or
encephalopathy. The reported 1-, 3-, and 5-year overall
survival rates were 91.0%, 64.1% and 41.3%, respectively,
for the RFA group and 92.2%, 51.7%, and 38.5% for the
microwave ablation group, without any statistically
significant difference (p=0.780). The 1-, 3-, and 5-year
disease-free survival rates were 70.5%, 42.3%, and 34.2%,
respectively, for the RFA group and 62.3%, 33.8%, and
20.8% for the microwave ablation group; even in this case no
statistically significant difference was noted. Interestingly, for
the subgroup of patients with tumor diameters of 3.1-5.0 cm,
the disease-free survival curve for the RFA-treated group was
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Table III. Outcomes of the most relevant studies on multimodal treatment. 
Author (Ref)                    Year      n. of patients    Type of study   Study interval                 Study design                                 Major outcomes
Shibata et al. (39)           2009              89                  P-RT/S           2003-2007        Patients with HCC nodules         No significant difference was 
                                                                                                                                    0.8-3.0 cm in diameter were        found between the two groups
                                                                                                                                         randomly treated with                   in terms of local tumor 
                                                                                                                                      combined RFA and TACE             progression, OS and local 
                                                                                                                                            or with RFA alone                     progression-free survival
Morimoto et al. (40)       2010              37                  P-RT/S           2005-2009       Patients with solitary HCCs           No statistically significant 
                                                                                                                                (diameter, 3.1-5.0 cm) randomly    difference was found between 
                                                                                                                                   assigned to 2 groups: TACE+          the two groups in terms of 
                                                                                                                                     RFA group, and RFA group       overall recurrence rate and 1- to 
                                                                                                                                                                                           3-year survival rates (p=0.390 
                                                                                                                                                                                              and p=0.369 respectively)
Kagawa et al. (42)          2010             117                    R/S              2000-2005       Patients receives TACE and           No statistically significant 
                                                                                                                                    RFA or surgical resection as      difference between TACE+RFA 
                                                                                                                                    the initial curative treatment            group and surgery group, 
                                                                                                                                     for single HCC <50 mm or         while recurrence-free survival 
                                                                                                                                        up to 3 HCCs <30 mm                was higher in the surgical 
                                                                                                                                                                                                       group (p=0.01)
Kim et al. (41)                2011             123                    R/S              2000-2010         Compare the effectiveness             Cumulative 1-, 3-, 5-, and 
                                                                                                                                   of combined TACE and RFA       7-year local tumor progression
                                                                                                                               with that of RFA alone in patients   rates were significantly lower 
                                                                                                                                 with medium sized (3.1-5.0 cm)     in the TACE+RFA than in the 
                                                                                                                                       hepatocellular carcinoma             RFA-alone group (p<0.001)
Kim et al. (43)                2013              84                     R/S              2008-2010      Compare the effectiveness of     RFA combined with TACE gave 
                                                                                                                                     RFA combined with TACE            similar results in terms of 
                                                                                                                                      with surgical resection in           recurrence-free and OS rates
                                                                                                                                     patients with a single HCC 
                                                                                                                                        ranging from 2 to 5 cm                                     
Yin et al. (44)                 2015             211                    R/S              2005-2011         Evaluate the effectiveness              Post treatment 1-, 3- and 
                                                                                                                                        of RFA in patients with               5-year cumulative OS was 
                                                                                                                                   intermediate (BCLC B) stage           89.8%, 61.1% and 37.4% 
                                                                                                                                   hepatocellular carcinoma who        respectively in TACE+RFA 
                                                                                                                                             underwent TACE                   group versus 67.2%, 36.6% 
                                                                                                                                                                                                   and 16.5% in TACE 
                                                                                                                                                                                                   alone group (p=0.01)
HCC: Hepatocellular carcinoma; M: multicentric; MVI: microvascular invasion; OS: overall survival; P: prospective; PEI: percutaneous ethanol
injection; R: retrospective; RFA: radiofrequency ablation; RT: randomized trial; S: single center; TACE: trans-arterial chemo-embolization.
significantly better than that for the microwave ablation-
treated group (log-rank test, p=0.018).
Later in 2015, Ginsburg and colleagues compared the
efficacy of a combined TACE plus RFA therapy versus
TACE plus microwave ablation (33). Eighty-nine patients
with HCC received TACE plus RFA (38 patients) or TACE
plus microwave ablation (51 patients), without any
statistically significant difference between the two groups in
patient demographics, including age, sex, and etiology of
liver cirrhosis, and no significant difference in tumor
characteristics, including tumor size, number of tumors, and
BCLC staging. The authors did not find any statistically
significant difference between these two approaches in terms
of overall progression-free survival and overall survival.
TACE. Kirikoshi and colleagues reported a retrospective study
in 2009 which compared the effects of TACE and of
combined therapies (TACE plus PEI or TACE plus RFA) on
long-term survival (34). The following eligibility criteria were
employed:previously untreated patients, and no history of
previous surgical treatments such as hepatic resection or liver
transplantation. Exclusion criteria were as follow: poor
hepatic function (CTP class C, especially presence of poorly
controlled hepatic encephalopathy or ascites); presence of
extra-hepatic metastasis; vascular contraindications to
chemoembolization (hepatic artery thrombosis, main portal
vein thrombosis, arteriovenous shunting); poor performance
status. Patients with multiple nodules (<3) having a diameter
<3 cm each were treated by PEI or RFA alone when all the
lesions could be identified using ultrasound. If not, or in
patients with more than three nodules, TACE alone was
performed. Combined therapy (TACE plus PEI/RFA) was
administered to the following patients: those with nodules
fulfilling the Milan Criteria, but in whom some of the HCC
lesions could not be detected by ultrasound; those with a
single lesion measuring more than 3 cm in diameter; those
with a large main lesion with small intra-hepatic metastasis
and more than three lesions. When TACE alone was
compared to palliative group, the median survival time was
significantly superior [24.9 months (range=2-30 months), vs.
10.4 months (range=2-63 months), p=0.0006]. Moreover, the
cumulative survival rates in the TACE-alone group were
significantly superior to those in the palliative treatment
group, being 98.2% at 6 months, 90.2% at 1 year, 55.9% at
2 years and 16.3% at 5 years (p<0.0001). When comparing
combined therapy to TACE alone, both the median survival
time [46.6 months (range=9-114 months) vs. 24.9 months
(range 2-30 months), p<0.0001] and the cumulative survival
rates (100%, 97.2%, 86.7% and 53.5% versus 98.2%, 90.2%,
55.9% and 16.3% at 6-months, and 1, 2 and 5 years,
respectively, p<0.0001) were in favor of the combined-
therapy group. On the other hand, the authors did not find any
statistically significant difference when comparing RFA/PEI
to combined therapy (p=0.09 and p=0.72 for median survival
time and cumulative survival rates, respectively). 
In 2014, Jin and colleagues in their retrospective study
reported the outcomes of 68 patients who underwent either
TACE or surgery/RFA for recurrent HCC after an initial
surgical approach (35). Cumulative overall survival rates at
1, 3, and 5 years after re-treatment were 65.1%, 27.9% and
18.6%, respectively, in the surgery/RFA group, and 91.2%,
66.1% and 30.0%, respectively, in the TACE group (p=0.23).
They also performed a subgroup analysis of patients treated
with no residual disease after treatment (so-called ‘R0’
resection): although with a marginal statistical significance,
patients with microvascular infiltration (MVI) treated with
TACE (10 patients) had a higher recurrence-free survival
than patients who underwent surgery/RFA (p=0.054).
Overall survival in patients with MVI was also significantly
higher in the TACE-treated group versus that treated with
surgery/RFA (p=0.01). Wang and colleagues published a
prospective study in 2015 comparing surgery, RFA and
TACE in patients who developed intrahepatic tumor
recurrence after partial hepatectomy (36). They used the
following inclusion criteria: R0 resection for primary HCC;
recurrent tumors met the Milan criteria; no evidence of
extrahepatic metastasis; liver function of CTP class score <8,
without severe esophageal varices; re-hepatectomy, RFA or
TACE as the first-line treatment for recurrence. The results
show that the 1, 3, and 5-year overall survival rates were
97.7%, 84.1% and 64.5% for the re-hepatectomy group,
88.4%, 55.8% and 27.7% for the TACE group, and 96.9%,
73.4% and 37.0% for the RFA group (re-hepatectomy vs.
TACE, p<0.001; vs. RFA, p=0.005; TACE vs. RFA,
p<0.001). The 1, 3-, and 5-year recurrence to death survival
(RTDS) rates were 94.5%, 71.5% and 43.0% for the re-
hepatectomy group, 76.6%, 39.3% and 8.3% for the TACE
group, and 90.4%, 53.7% and 26.7% for the RFA group
(rehepatectomy vs. TACE, p<0.001; vs. RFA, p=0.008;
TACE vs. RFA, p<0.001).
Radioembolization. Khor et al. in 2014 reported a
retrospective study of patients, all with normal renal function,
with unresectable tumors and portal vein thrombosis (PVT)
or tumors larger than 3 cm that were not amenable to RFA
who were considered for radioembolization (37). The median
reported overall survival was 14.4 months (95% CI=11.0-22.2
months). They clarified that patients with CTP class A disease
fared better compared to those with CTP class B disease (21.7
vs. 7.1 months, respectively; p=0.0001). Moreover, patients
without vascular invasion had significantly better median
survival compared to patients with vascular invasion (18.1 vs.
11.0 months, respectively; p=0.02).
Bhangoo et al. in 2015 reported the effects of yttrium-90
(Y-90) radioembolization in a population of 17 patients with
unresectable HCC who either had failed or had disease not
amenable to alternative locoregional therapies (38). The
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inclusion criteria were age of 18 years or more; ECOG
performance status 0-2; serum total bilirubin less than 2 mg/l;
ability to undergo angiography. Conversely, exclusion criteria
included were uncorrectable flow to the gastrointestinal tract,
significant extrahepatic disease, applied lung dose greater
than 30 Gy in a single fraction, and CTP class C cirrhosis.
The authors reported a median survival of 8.4 months
(range=1.3 to 21.1 months) after their first radioembolization
treatment, and a mean overall survival from the time of
diagnosis of 11.7 months (range=3.4-43.2 months). 
Multimodal treatments. In 2009, Shibata and colleagues
reported their experience in a prospective randomized trial
comparing TACE plus RFA versus RFA alone in patients
fulfilling the following inclusion criteria: three or fewer HCC
nodules 3 cm in diameter or smaller, CTP class A or B
cirrhosis, no imaging evidence of tumor invasion into the major
portal or hepatic vein branches, no extrahepatic metastasis, and
a platelet count of more than 40,000 cells/mm3 (39). A total of
89 patients entered the study, 46 in the combined therapy group
and 43 in that for RFA alone. Local tumor progression, overall
survival and local progression-free survival rates at 1-, 2-, 3-
and 4-years did not differ significantly between the RFA group
and combined-treatment group (p=0.797, p=0.515 and
p=0.934, respectively). 
Morimoto and colleagues presented a randomized trial in
2010 also comparing the midterm outcomes of TACE plus
RFA versus RFA alone (40). The following inclusion criteria
were met by 37 patients that did not receive any other
previous treatment for HCC: ECOG performance status score
of 2 or less; CTP class A or B; solitary lesion; maximum
tumor diameter of 3.1-5.0 cm; lesion detected by
ultrasonography; divergence of the hepatic artery suitable for
TACE; no evidence of portal or venous thrombosis,
extrahepatic metastasis, or uncontrollable ascites; adequate
hematologic function (platelet count >50×109 cells/l,
hemoglobin >8.0 g/dl, and prothrombin time <80%); adequate
hepatic function (albumin >2.5 g/dl, total bilirubin <3 mg/dl,
and alanine aminotransferase and aspartate aminotransferase
levels <5×the upper limit of the normal range); and adequate
renal function (serum creatinine concentration <1.5×the upper
limit of the normal range). A total of 18 patients were assigned
to the RFA group, and 19 to the TACE-RFA group, technical
success was obtained in all 37 patients. Local tumor
progression rate in the RFA group was 39% at the end of the
first, second, and third years, while in the TACE-RFA group
it was correspondingly 6% (log-rank test, p=0.012).
Conversely, no statistically significant difference was found
between the two groups in terms of overall recurrence rate and
1-to 3-year survival rates (p=0.390 and p=0.369 respectively). 
Later in 2011, Kim and colleagues reported their
experience with a cohort of 123 patients to compare the
effectiveness of combined TACE and RFA with that of RFA
alone in patients with medium-sized (3.1-5.0 cm)
hepatocellular carcinoma (41). Patients were eligible to be
included in the study if they had a single HCC >3 cm but 
≤5 cm in the largest diameter, no imaging evidence of
vascular invasion by the tumor, and no evidence of
extrahepatic disease. Patients also were included if they were
not candidates for surgical resection based on the liver
function, if they had unpredictable transplantation time
during waiting period for liver transplantation, or if they
refused to undergo surgery or liver transplantation. From
March 2000 to March 2010, 66 patients underwent RFA
alone and 57 patients TACE plus RFA. The cumulative 1-,
3-, 5-, and 7-year local tumor progression rates in the TACE
plus RFA group were 9%, 40%, 55% and 66%, respectively,
significantly lower than the rates of 45%, 76%, 86%, and
89%, respectively, in the RFA-alone group (p<0.001). At
multivariate analysis, treatment allocation (OR=1.78; 95%
CI=1.12-2.83; p=0.016) and CTP class (OR=1.96; 95%
CI=1.19-3.23; p=0.008) were significant independent factors
associated with patient survival.
In 2010, Kagawa and colleagues reported the outcomes of
a study involving 117 patients undergoing TACE followed
by RFA within 2 months (62 patients) or surgery alone (55
patients) for early HCC (42). Inclusion criteria were no
previous treatment for HCC, a single HCC <50 mm or up to
three HCCs <30 mm, cirrhosis classified as CTP class A, no
vascular invasion, and no extrahepatic metastasis, while
exclusion criteria were ECOG performance status >2 and
presence of an uncontrollable malignancy other than HCC.
Overall survival at 1, 3, and 5 years were 100%, 94.8% and
64.6% in the TACE plus RFA group, and 92.5%, 82.7% and
76.9% in the resection group, respectively, without any
statistically significant difference (p=0.788 by log-rank test).
Conversely, recurrence-free survival rates at 1, 3, and 5 years
were 64.5%, 40.1% and 18.0% in the TACE-RFA group, and
75.6%, 41.1%, and 36.4% in the resection group,
respectively (p=0.01 by log-rank test).
Similarly in 2013, Kim et al. compared the outcomes of
TACE combined with RFA versus surgery alone in a series
of 84 patients affected by HCC (43). The following inclusion
criteria were considered for that study: a single HCC of 
2-5 cm in the largest dimension, no history of prior treatment
for HCC, no major vascular invasion and no evidence of
extrahepatic tumor. The length of hospital stay after the
procedure was significantly longer in the surgically resected
group (19.8±8.4 days) than in the combined therapy group
(7.4±2.2 days) (p<0.0001). Recurrence-free survival rates at
1, 2, 3 and 4 years were 89.2%, 75.2%, 69.4% and 69.4%,
respectively, in the combined-therapy group and 81.8%,
68.5%, 68.5% and 65%, respectively, in the surgically-
resected group, without any statistically significant
difference between the two groups (p=0.7962). Overall
survival rates at 1, 2, 3 and 4 years were not significantly
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different (p=0.63210), as they were 97.3%, 86.5%, 78.4%
and 78.4%, respectively, in the combined therapy group, and
95.7%, 89.4%, 84.3% and 80.3%, respectively, in the
surgical resection group. 
In their article, Yin and colleagues present a single-center
study of patients undergoing TACE alone versus TACE and
RFA (44). They reported the following inclusion criteria: the
presence of a single HCC tumor ≤8 cm in diameter, or multi-
nodular HCC tumors (n≤5) smaller than 5 cm in diameter
before initial TACE; the presence of viable residual HCC
with retained iodized oil after TACE as shown by the follow-
up liver CT and/or MRI scan; the absence of portal vein
invasion and extrahepatic metastasis; and CTP class A or B.
55 patients received combined RFA treatment based on the
following criteria: viable residual tumors after TACE could
be detected by follow-up ultrasonography, residual tumors
could be possibly ablated with curative intention by RFA;
absence of severe coagulopathies, such as prothrombin time
≤16 s or platelet count >50,000/ml; and patients who signed
informed consent for RFA. The other 156 patients who were
not suitable for RFA and received repeated TACE treatment
were assigned to TACE alone group based on the following
reasons: tumors were poorly visible on planning ultrasound;
percutaneous RFA was infeasible due to the high-risk
location of thermal injury or could result in incomplete
ablation due to the inadequate electrode path; coagulopathy
such as prothrombin time >16 s or platelet count <50,000/ml;
and unwillingness to receive additional RFA treatment due
to economic or other personal reasons, although residual
tumors could be treated with combined RFA. The results
showed that in TACE plus RFA group (n=55), complete
response, partial response, stable disease and progressive
disease rates were 60%, 10.9% and 3.6% and 25.5%,
respectively, versus 11.5%, 20.5%, 22.4% and 45.5%,
respectively, in TACE alone group (n=156). Moreover, the
reported cumulative 1-, 3-, and 5-year tumor progression
rates in TACE alone group were 71.4%, 98.3% and 100%,
respectively, which were significantly higher than 36.0%,
81.6% and 90.8% in the TACE+RFA group (p<0.001).
Lastly, the post treatment 1-, 3- and 5-year cumulative
overall survival rates were 89.8%, 61.1% and 37.4%,
respectively, in TACE+RFA group versus 67.2%, 36.6% and
16.5% in TACE alone group (p=0.01).
Discussion
Surgical resection remains the standard treatment for patients
with a single nodule, preserved liver function, and good
performance status. According to the most recent data, it is
associated with 5-year survival rates up to 70% and 2% to
3% perioperative mortality in patients with cirrhosis.
Moreover, some authors report 5-year survival rates above
50% in patients undergoing resection for a single lesion 
≤5 cm, or up to three lesions ≤3 cm each [Milan criteria (45)]
but who were not fit for transplantation (46). As previously
reported, laparoscopic technique with an accurate ultrasound
examination of liver parenchyma can allow for a complete
exclusion of hepatic lesions undetectable at the preoperative
imaging and provides the minimal onset of adhesions, which
is extremely useful in patients undergoing liver
transplantation (47). However, liver transplantation performed
in patients fulfilling the Milan criteria results in a 5-year
overall survival rate of 75%, with a risk of recurrence of
<15%, with perioperative mortality and 1-year mortality of
approximately 3% and ≤10%, respectively (46). As a matter
of fact, liver transplantation is the most effective therapy for
cirrhosis, the underlying liver disease that causes HCC (48).
Therefore what is the role of local treatment of HCC? 
As reported by Wang et al. in a recent review, PEI and
RFA are widely used in clinical practice (49). The major
pitfalls of these two techniques are the poor efficacy of PEI
in tumors greater than 2 cm and the use of RFA in tumors
close to major vessels. This is due to the distribution of
ethanol that may be blocked by the intratumoral fibrotic
septa or the tumor capsule, resulting in a heterogeneous
distribution. Conversely, RFA results in coagulative necrosis
of both the tumor and the surrounding parenchymal tissue,
also being effective on small undetected satellites. Besides
the potential vascular damage when tumors are close to great
vessels, the heat-sink effect may result in incomplete
ablation (16). However, RFA has been shown to be as
effective as hepatic resection in the treatment of small single-
nodule HCC. Moreover, it has been shown that RFA is
related to better overall survival compared to PEI regardless
of tumor size (31).
Even if not statistically significant, data reported by Kim
et al. (26) show that surgery cannot be replaced by RFA
alone, especially in patients without severe liver disease who
are therefore amenable to radical treatments without high
risk of morbidity. The role of RFA for recurrent HCC after
front-line RFA has also been studied. We herein reported
data from Xie and colleagues that showed how RFA is
comparable to salvage liver resection (27). One major
limitation of their study is the bias in the patient selection
process: panel discussion with multidisciplinary treatment
team including surgeons, radiologists, oncologists, and
pathologists was performed to make a decision regarding the
optimal treatment modality for local recurrence. According
to the authors, RFA was recommended as the first choice for
favorable local recurrence (defined as tumor size ≤5 cm,
focality around prior ablation site, absence of macrovascular
invasion, and located >5 mm from important structures);
TACE was an alternative treatment for patients with
concurrent multiple or large intrahepatic metastases; when
local non-surgical treatment was deemed infeasible or failed,
salvage liver resection was recommended when liver
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function reserve was enough and all radiology-found tumors
were located within one lobe. Similarly, according to Chang
and colleagues, RFA can improve long-term outcomes after
incomplete TACE, with results comparable to RFA alone
(28). No statistically significant difference was demonstrated
in terms of overall survival when comparing RFA versus
PEI, surgery versus TACE/TAE, and RFA/PEI versus
TACE/TAE according Signoriello and colleagues (29). This
study, an interesting attempt to collect multicentric data from
an Italian region, has a major limitation in being
retrospective and grouping together all HCCs regardless of
size, without specifying the indication for each treatment.
Therefore, such data may be confusing.
TACE is reported to be more effective than surgery or
RFA in patients with early recurrence and MVI after curative
resection, staged as BCLC 0 or A (35). Despite its
retrospective setting, lack of randomization and small sample
size, this article contributed to the discussion on which
treatment should be preferred for recurrent HCCs as a bridge
to salvage transplantation. As previously reported, the
absence of active residual HCC in the native liver at
histological examination after liver transplantation in patients
who had undergone bridging therapies was a highly positive
prognostic factor in regard to HCC recurrence and overall
patient survival (50). Moreover, an aggressive treatment of
HCC with liver resection, TACE, and RFA is necessary for
down-staging and is able to qualify patients for transplant
(51). Later in 2015, in a prospective study Wang and
colleagues reported that in patients treated for recurrence
after curative hemi-hepatectomy, the repeat hepatectomy
group had significantly better overall survival and RTDS
than the RFA group, and that of the RFA group was
significantly better than that of the TACE group (36).
The approach with TACE versus palliative care in patients
with more than three HCC nodules showed significantly
greater efficacy according to Kirikoshi and colleagues (34).
However, combined therapy with TACE plus PEI/RFA
resulted in better outcomes versus TACE alone, also when
exceeding the Milan Criteria (p=0.0024). The authors also
reported that there was no statistically significant difference
between PEI/RFA alone versus combined therapy. Although
the setting of this study was not prospective, with potential
biases due to its retrospective nature, it shows that combined
therapies are not superior to RFA alone for intermediate
HCCs. More data about this interesting topic came from other
articles presenting multimodal approaches to resectable HCC.
In 2011 Kim and colleagues reported that cumulative 1-, 3-,
5-, and 7-year local tumor progression rates were significantly
lower in the TACE+RFA than in the RFA-alone group
(p<0.001) in patients with medium-sized HCC (41). Although
remarkable, the results of this study are biased by its
retrospective and non-randomized design. Kagawa and Kim
reported their results comparing surgical resection and
combined approach of TACE followed by RFA. They reported
no differences in terms of overall survival, while recurrence-
free survival was in favor of the surgical approach (p=0.01),
whereas in the study from Kim and colleagues, no significant
difference was found in terms of recurrence-free and overall
survival between the two approaches (42, 43). The two studies
differ for the timing of RFA, which was scheduled on the day
after TACE in the study by Kim et al., while in the study of
Kagawa et al., it was performed within 2 months of TACE. In
both cases, the results are biased from the small number of
patients and the non-randomized nature of the studies.
According to Kim et al., indication to perform either surgical
or local treatment was given by an institution hepatobiliary
team, excluding from surgery patients that wanted to undergo
nonsurgical treatment (n=22), patients with inappropriate
hepatic functional reserve (n=9), and patients with small
volume of remnant liver after surgery (n = 6) (43). In their
well-written article, Yin and colleagues reported that the total
tumor control rate was 74.5% in the TACE plus RFA group
versus 54.5% in the TACE alone group (p<0.001) (44). After
stratification for tumor number and size, neither 1-, 3-, and 5-
year tumor progression rates nor overall survival significantly
differed between the single-tumor group and multi-tumor
group. It seems relevant that the two randomized trials
reported (39, 40) failed to demonstrate a statistically
significant advantage for the TACE plus RFA combination
versus RFA alone in a cohort of small and intermediate-sized
HCCs. As a matter of fact, Morimoto and colleagues
demonstrated that such a combination therapy is safe and
effective for extending the ablated area, thereby contributing
to restricting local tumor progression, but a larger number of
patients may be needed to confirm the survival benefits (40).
Conversely, Shibata et al. showed that the addition of TACE
to RFA for HCCs of 3 cm or smaller does not appear to be
warranted since local tumor progression rates, overall survival
rates, and local progression-free survival rates were equivalent
to those of patients who underwent RFA alone (39). 
As previously underlined, further studies should evaluate the
applicability, the safety and the outcome after aggressive
treatments in patients with advanced HCC, such as portal vein
embolization, prior extended hepatectomies, combined
locoregional treatments and chemotherapy protocols in our
constantly aging society (52). For example, sarcopenia was
associated with worse outcomes in patients who underwent
liver resection or liver transplantation for HCC and intrahepatic
cholangiocarcinoma, with an incidence of postoperative
complications of 40.4% among patients with sarcopenia versus
18.4% among patients without (p=0.01) (53). In an interesting
article published in 2013, Nathan and colleagues addressed the
hypothesis that non-clinical factors, i.e. hospital- or surgeon-
related factors, may drive the decision of which approach
should be adopted for early HCCs (54). Four major groups for
analysis were considered: liver transplantation and RFA, with
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or without liver resection (41%); liver transplantation but not
RFA, with or without liver resection (14%); liver resection and
RFA, but not liver transplantation (39%); and liver resection
but not RFA or liver transplantation (6%). Significant
predictors of choice of therapy included practice type, with
academic surgeons favoring liver resection (relative risk
ratio=1.71; 95% CI=0.97-3.02) and LT (relative risk ratio=2.42;
95% CI=1.34-4.36) over RFA more strongly than private-
practice surgeons (p=0.09). Annual HCC patient volume also
impacted choice of therapy, with higher-volume surgeons
favoring transplantation over resection. Of note, non-
transplantation surgeons were more likely than transplantation
surgeons to choose resection and RFA over transplantation.
However, surgeons who did not personally perform
transplantation but worked at hospitals that offered it were less
likely to choose RFA than those who worked at hospitals
without transplantation (p=0.001). This clearly reflects the
confusion present in literature and the lack of definitive data. 
Conclusion
Data in the literature are confusing and difficult to compare
due to the lack of prospective studies. Overall, we believe
that a multidisciplinary panel should provide a tailored
approach for each patient, considering both guideline
indications and patient-specific characteristics, and
enhancing the hospital-specific best practice. The trend in the
evaluation of HCC is still bi-dimensional, focusing on tumor
dimension and number as prognostic factors and key
elements in the decision-making process of HCC. We believe
that in the near future’ the genetic fingerprint of HCC will
play a growing role, modifying both staging and indications
for treatment, according to a new three-dimensional system.
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